These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 38719428)

  • 1. Response letter by Nassar et al.
    Nassar AH; Kim SY; Adib E; Naqash AR; Goldberg SB
    J Thorac Oncol; 2024 May; 19(5):e7-e8. PubMed ID: 38719428
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to the letter to the editor 'How much evidence isn't in evidence-based guidelines?' by Johnson et al.
    Cherny NI; Kloke M; Cervantes A; Pentheroudakis G;
    Ann Oncol; 2016 Mar; 27(3):550-1. PubMed ID: 26602775
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to "Letter to the editor of radiotherapy and oncology regarding of the article "Dosimetric parameters related to occurrence of distant metastases and regional nodal relapse after SBRT for early-stage non-small cell lung cancer" by Lalonde et al.".
    Lalonde R; Abdelhakiem M; Keller A; Huq MS
    Radiother Oncol; 2022 Dec; 177():242. PubMed ID: 35716840
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter to the editor of radiotherapy and oncology regarding of the article "Dosimetric parameters related to occurrence of distant metastases and regional nodal relapse after SBRT for early-stage non-small cell lung cancer" by Lalonde et al.
    Yang K; Sun C; Yin R
    Radiother Oncol; 2022 Dec; 177():240-241. PubMed ID: 35716839
    [No Abstract]   [Full Text] [Related]  

  • 5. Comment on Rosell et al., Roth et al. and Gandara et al., Lung Cancer.
    Grannis FW
    Lung Cancer; 2000 Jun; 28(3):247-51. PubMed ID: 10917719
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to letter to the editor regarding "External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts" by M. Berbée et al.
    Berbée M; Muijs CT; Schuit E
    Radiother Oncol; 2024 Apr; 193():110176. PubMed ID: 38373573
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to "Letter to the Editor" From David Y. Mak et al.
    Kenmotsu H; Mori K; Nakagawa K; Yamamoto N; Takahashi T
    J Thorac Oncol; 2023 Jan; 18(1):e4-e5. PubMed ID: 36543438
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to the Letter to the Editor by C. Nicolazzo et al.: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy".
    Alama A; Coco S; Vanni I; Grossi F
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to Letter to Editor by Cornelissen et al.
    Hassan R; Miettinen M
    J Thorac Oncol; 2020 Oct; 15(10):e169-e170. PubMed ID: 32981607
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to letter to the editor by Cohen et al. (2014) "Re: Waalkes et al.: Lung tumors in mice induced by "whole-life" inorganic arsenic exposure at human-relevant doses, Arch Toxicol, 2014".
    Waalkes MP; Qu W; Tokar EJ; Kissling GE; Dixon D
    Arch Toxicol; 2014 Nov; 88(11):2063-5. PubMed ID: 25253650
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to letter by Farioli
    Reid A; Franklin P; Berry G; Peters S; Sodhi-Berry N; Brims F; Musk AW; de Klerk NH
    Occup Environ Med; 2019 May; 76(5):356. PubMed ID: 30928905
    [No Abstract]   [Full Text] [Related]  

  • 12. Letter to the editor regarding "External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts" by M. Berbée et al.
    Populaire P; Defraene G; Haustermans K
    Radiother Oncol; 2024 Apr; 193():110175. PubMed ID: 38417534
    [No Abstract]   [Full Text] [Related]  

  • 13. The distinction of small cell and non-small cell lung cancer by growth in native-state histoculture.
    Vescio RA; Connors KM; Bordin GM; Robb JA; Youngkin T; Umbreit JN; Hoffman RM
    Cancer Res; 1990 Sep; 50(18):6095-9. PubMed ID: 2168289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reply to the Letter to the Editor From Zhou et al.
    Dagogo-Jack I; Mino-Kenudson M
    J Thorac Oncol; 2020 Aug; 15(8):e136-e137. PubMed ID: 32718538
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply to the Letter to the Editor by Hendriks et al.
    Eberhardt WE; Mitchell A; Rami-Porta R
    J Thorac Oncol; 2016 Mar; 11(3):e43-4. PubMed ID: 26922925
    [No Abstract]   [Full Text] [Related]  

  • 16. Lung metastases from benign uterine leiomyoma: does 18-FDG-PET/CT have a role to play?
    Abu Saadeh F; Riain CO; Cormack CM; Gleeson N
    Ir J Med Sci; 2019 May; 188(2):619-624. PubMed ID: 30074141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letter in response to paper by Abratt et al., Cancer Chemother Pharmacol (1992) 30: 495.
    Senan S
    Cancer Chemother Pharmacol; 1993; 31(6):500-1. PubMed ID: 8384087
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter to the Editor: Exposure-response or clearance-response relationship in immune checkpoint therapy?-A comment on 'correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer' by Basak et al.
    Badawi M; Coss CC; Phelps MA
    Eur J Cancer; 2019 Jun; 114():25-26. PubMed ID: 31009820
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to the Letter to the Editor From He Y et al.
    Okubo Y; Yatabe Y
    J Thorac Oncol; 2023 May; 18(5):e46-e48. PubMed ID: 37087120
    [No Abstract]   [Full Text] [Related]  

  • 20. Letter to the Editor about Sorich et al.
    Mezquita L; Auclin E; Besse B
    J Thorac Oncol; 2019 Sep; 14(9):e209. PubMed ID: 31445741
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.